Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
Home > Products > Novel inhibitors

Novel inhibitors

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DCC2404 Gsk702
Negative control for GSK699
More description
DCC2403 Gsk699
Novel PCAF/GCN5 degrader, modulating PCAF/GCN5 immune cell function through a PROTAC approach
More description
DCC2402 Gsk6776
Novel, soluble, permeable, and selective BRD7/9 inhibitor
More description
DCC2401 Gsk635416a
Novel ATM inhibitor with cancer cell specific radiosensitization activity
More description
DCC2400 Gsk579289a
Potent polo-like kinase 1 (PLK1) inhibitor
More description
DCC2399 Gsk5750
Novel inhibitor of the Ribonuclease H Activity of HIV-1 Reverse Transcriptase
More description
DCC2398 Gsk572a
Novel potent EchA6 inhibitor
More description
DCC2397 Gsk557296
Novel highly potent and selective non-peptide oxytocin receptor antagonist
More description
DCC2396 Gsk466317a
Novel selective inhibitor of G protein-coupled receptor kinase 2 (GRK2)
More description
DCC2395 Gsk452
Novel, Potent, Selective, and Highly Soluble Bromo and Extraterminal Domain (BET) Second Bromodomain (BD2) Inhibitor
More description
DCC2394 Gsk41364a
Novel specific inhibitor of polo-like kinase 1 (PLK-1), inducing cell death by causing cell cycle arrest at G2/M phase by competing with the ATP binding site of PLK-1 thus leading to apoptosis
More description
DCC2393 Gsk4028
Negative control for GSK4027
More description
DCC2392 Gsk-3ß/hdac Inhibitor C11
First-in-Class GSK-3β/HDAC Dual Inhibitor as a Disease-Modifying Agent To Combat Alzheimer’s Disease
More description
DCC2391 Gsk3-in-40
Potent and irreversible inhibitor of GSK3
More description
DCC2389 Gsk3i Xv
Novel highly potent cell-permeable, reversible, ATP-competitive inhibitor of GSK-3 (IC50 = 0.4 and 0.6 nM for GSK-3α and GSK-3β, respectively)
More description
DCC2388 Gsk3830052
Novel DNMT1-selective inhibitor (IC 50 = 0.11 ± 0.02 µM)
More description
DCC2387 Gsk366a
Novel anti-TB agent against Mycobacterium tuberculosis and Mycobacterium bovis BCG, targeting MmpL3 and inhibiting EchA6
More description
DCC2386 Gsk360a
Novel inhibitor of prolyl hydroxylase (PHD) domain-containing enzyme
More description
DCC2385 Gsk-354
Novel lysine specific histone demethylase 1 (LSD1) inhibitor, exhibiting high selectivity to LSD1 over MAOs
More description
DCC2384 Gsk334429
Novel selective non-imidazole histamine H 3 receptor antagonist
More description
DCC2383 Gsk3277329
Novel agonist of toll-like receptor 2 (TLR2), stimulating the release of G-CSF in activated THP-1 cells, peripheral blood mononuclear cells, and human umbilical vein endothelial cells
More description
DCC2382 Gsk3182571
Promiscuous kinase inhibitor, a close analog of CTx-0294885
More description
DCC2381 Gsk317354a
Novel selective inhibitor of G protein-coupled receptor kinase 2 (GRK2)
More description
DCC2380 gsk314181a
Potent and selective antagonist of P2X7 receptor
More description
DCC2379 Gsk3038548a
Novel potent RORγ inverse agonist
More description
DCC2378 Gsk-3008348-n1-methyl
Novel quaternized GSK-3008348 derivative, acting as a highly selective αvβ6 Integrin Inhibitor
More description
DCC2377 Gsk299115a
Novel inhbitor of protein kinase GRK1/2/5 and PKA
More description
DCC2376 Gsk2838232
Novel human immune virus (HIV) maturation inhibitor
More description
DCC2375 Gsk-2807
Novel potent and selective, SAM-competitive inhibitor of SMYD3
More description
DCC2374 Gsk270822a
Novel selective inhibitor of G protein-coupled receptor kinase 2 (GRK2)
More description

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X